Karl Broich

from Wikipedia, the free encyclopedia

Karl Broich [ bʁoːχ ] (born October 1, 1959 ) is a German doctor and psychiatrist . He has been President of the Federal Institute for Drugs and Medical Devices (BfArM) since 2014 .

Life

After studying human medicine at the Rheinische Friedrich-Wilhelms-Universität Bonn , Broich began his specialist training in neurology and psychiatry in Bonn in 1985 . From 1990 to 1991, during a research stay at the University of Pennsylvania , he dealt with the PET and SPECT imaging of neurotransmitter receptors in neurodegenerative diseases. After his specialist examination, Broich worked from 1993 as a senior physician and from 1997 as a senior senior physician at the clinic and polyclinic for psychiatry and psychotherapy at the Martin Luther University in Halle-Wittenberg . In 2000 he moved to the Federal Institute for Drugs and Medical Devices in Bonn as head of department for neurology and psychiatry, where he was head of the approval department 4 from 2005 . In 2009 Broich was appointed Vice President of the BfArM. He has been President of the BfArM since August 2014, succeeding Walter Schwerdtfeger .

Karl Broich has been honorary professor at the Medical Faculty of the Rheinische Friedrich-Wilhelms-Universität Bonn since 2013. He was involved in more than 120 scientific publications. Broich is active in various committees of the European Medicines Agency (EMA). Broich has been chairman of the working group for the central nervous system at EMA since 2013.

Memberships

Fonts (selection)

  • K. Broich, A. Hartmann, HJ Biersack, R. Horn: Crossed cerebello-cerebral diaschisis in a patient with cerebellar infarction. In: Neuroscience letters. Volume 83, Number 1-2, December 1987, pp. 7-12, ISSN  0304-3940 . PMID 3441301 .
  • K. Broich, S. Adam, A. Hartmann, HJ Biersack, F. Grünwald: [Disorders of regional cerebrovascular circulation and neuropsychological findings in dementia of the Alzheimer type]. In: The neurologist. Volume 60, Number 3, March 1989, pp. 141-148, ISSN  0028-2804 . PMID 2785658 .
  • K. Broich, D. Horwich, A. Alavi: HMPAO-SPECT and MRI in acute disseminated encephalomyelitis. In: Journal of nuclear medicine: official publication, Society of Nuclear Medicine. Volume 32, Number 10, October 1991, pp. 1897-1900, ISSN  0161-5505 . PMID 1919728 .
  • K. Broich, A. Alavi, M. Kushner: Positron emission tomography in cerebrovascular disorders. In: Seminars in nuclear medicine. Volume 22, Number 4, October 1992, pp. 224-232, ISSN  0001-2998 . PMID 1439868 . (Review).
  • K. Broich, S. Heinrich, A. Marneros: Acute clozapine overdose: plasma concentration and outcome. In: Pharmacopsychiatry . Volume 31, Number 4, July 1998, pp. 149-151, ISSN  0176-3679 . doi : 10.1055 / s-2007-979318 . PMID 9754851 .
  • K. Broich, F. Grünwald, S. Kasper, E. Klemm, HJ Biersack, HJ Möller: D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects. In: Pharmacopsychiatry. Volume 31, Number 5, September 1998, pp. 159-162, ISSN  0176-3679 . doi : 10.1055 / s-2007-979321 . PMID 9832346 .
  • K. Broich: [Clinical trials using antidepressants and antipsychotics. The pros and cons of placebo control]. In: Federal Health Gazette, Health Research, Health Protection. Volume 48, Number 5, May 2005, pp. 541-547, ISSN  1436-9990 . doi : 10.1007 / s00103-005-1038-1 . PMID 15887064 . (Review).
  • K. Broich: Regulatory issues in vascular dementia: a European perspective. In: International psychogeriatrics / IPA. Volume 15 Suppl 1, 2003, pp. 297-301, ISSN  1041-6102 . doi : 10.1017 / S1041610203009372 . PMID 16191258 .
  • K. Broich: Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective. In: International psychogeriatrics / IPA. Volume 19, Number 3, June 2007, pp. 509-524, ISSN  1041-6102 . doi : 10.1017 / S1041610207005273 . PMID 17433121 . (Review).
  • K. Broich, HJ Möller: Pharmacogenetics, pharmacogenomics and personalized psychiatry: are we there yet? In: European archives of psychiatry and clinical neuroscience. Volume 258 Suppl 1, March 2008, pp. 1-2, ISSN  0940-1334 . doi : 10.1007 / s00406-008-1001-x . PMID 18344042 .
  • K. Broich: Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants. In: European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. Volume 19, Number 5, May 2009, pp. 305-308, ISSN  1873-7862 . doi : 10.1016 / j.euroneuro.2009.01.012 . PMID 19269795 .
  • K. Broich, M. Weiergräber, H. Hampel: Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements. In: Progress in neurobiology. Volume 95, Number 4, December 2011, pp. 498-500, ISSN  1873-5118 . doi : 10.1016 / j.pneurobio.2011.09.004 . PMID 21945642 .
  • K. Broich, T. Bieber: [Personalized medicine]. In: Federal Health Gazette, Health Research, Health Protection. Volume 56, Number 11, November 2013, pp. 1465-1467, ISSN  1437-1588 . doi : 10.1007 / s00103-013-1843-x . PMID 24170074 .

Web links

Individual evidence

  1. ^ The curriculum vitae of Karl Broich on the BfArM website
  2. ↑ BMG press release of July 30, 2014: Prof. Dr. Karl Broich is to be appointed as the new President of the Federal Institute for Drugs and Medical Devices ( PDF ( Memento of the original from September 23, 2015 in the Internet Archive ) Info: The archive link has been inserted automatically and has not yet been checked. Please check the original and archive link according to instructions and then remove this notice.69KB) @1@ 2Template: Webachiv / IABot / www.bmg.bund.de
  3. ↑ Karl Broich's curriculum vitae on the EMA website ( PDF 106KB)
personal data
SURNAME Broich, Karl
BRIEF DESCRIPTION German doctor and psychiatrist
DATE OF BIRTH October 1, 1959